3
|
An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. Eur J Pharmacol 2008; 603:138-46. [PMID: 19103195 DOI: 10.1016/j.ejphar.2008.11.063] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2008] [Revised: 11/17/2008] [Accepted: 11/27/2008] [Indexed: 01/24/2023]
Abstract
Inhibition of the alpha4 subunit of both the alpha4beta1 and alpha4beta7 integrins has shown promise in decreasing airway inflammation and airway hyperresponsiveness in various animal models. We hypothesized that a novel, high-affinity alpha4beta1 antagonist (LLP2A) would decrease the migration of eosinophils to the lung and ameliorate the airway hyperresponsiveness in a mouse model of ovalbumin-induced airway inflammation. To test this hypothesis, we administered LLP2A, or scrambled LLP2A (a negative control), prior to exposure of sensitized BALB/c mice to ovalbumin aerosol. We can partially prevent, or reverse, the airway inflammatory response, but not airways hyperresponsiveness, by treatment of mice with LLP2A, a synthetic peptidomimetic alpha4beta1 antagonist. Specifically engineered, PEGylated (PEG) formulations of this antagonist further reduce the airway inflammatory response to ovalbumin, presumably by improving the circulating half-life of the drug.
Collapse
|
4
|
Pilkington-Miksa MA, Writer MJ, Sarkar S, Meng QH, Barker SE, Shamlou PA, Hailes HC, Hart SL, Tabor AB. Targeting Lipopolyplexes Using Bifunctional Peptides Incorporating Hydrophobic Spacer Amino Acids: Synthesis, Transfection, and Biophysical Studies. Bioconjug Chem 2007; 18:1800-10. [DOI: 10.1021/bc0700943] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Michael A. Pilkington-Miksa
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Michele J. Writer
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Supti Sarkar
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Qing-Hai Meng
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Suzie E. Barker
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Parviz Ayazi Shamlou
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Helen C. Hailes
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Stephen L. Hart
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| | - Alethea B. Tabor
- Departments of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London WC1H 0AJ, Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, and Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, United Kingdom
| |
Collapse
|
7
|
Abstract
Circulating lymphocytes normally migrate through extravascular spaces in relatively low numbers as important members of the immunosurveillance process. That is until signals are received by endothelial cells that there is an underlying infection or inflammatory condition. These vascular surface cells in turn overexpress and present ligands to circulating lymphocyte adhesion molecules. Upon encountering this higher density of ligands, lymphocytes, which had been leisurely rolling along the vascular surface, now become more firmly attached, change shape, and migrate through tight junctions to the sites of infection or inflammation. If the initiating events are not resolved and the condition becomes chronic, there can be a sustained extravasation of lymphocytes that can exacerbate the inflammatory condition, which in turn will continue to recruit more inflammatory cells resulting in unwanted tissue destruction. It is for the attenuation of this cycle of sustained inflammatory cell recruitment that very late activating antigen-4 (VLA-4) antagonists are being developed. Most lymphocytes, except neutrophils, express VLA-4 on their surface and they interact with endothelial vascular cell adhesion molecule-1 (VCAM-1). It is this interaction that VLA-4 antagonists are intended to disrupt, thus, putting an end to the cycle of chronic inflammation, which is the hallmark of many diseases. This review will provide an update of VLA-4 antagonists that have appeared since early 2001 and will discuss some of the issues, both positive and negative, that may be encountered in their development.
Collapse
Affiliation(s)
- Ginger X Yang
- Merck Research Laboratories, Rahway, New Jersey 07090, USA.
| | | |
Collapse
|
8
|
Kaneko T, Clark RSJ, Ohi N, Kawahara T, Akamatsu H, Ozaki F, Kamada A, Okano K, Yokohama H, Muramoto K, Ohkuro M, Takenaka O, Kobayashi S. Inhibitors of adhesion molecules expression; the synthesis and pharmacological properties of 10H-pyrazino[2,3-b][1,4]benzothiazine derivatives. Chem Pharm Bull (Tokyo) 2002; 50:922-9. [PMID: 12130850 DOI: 10.1248/cpb.50.922] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
During a search for novel, orally-active inhibitors of upregulation of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), we found a new series of 10H-pyrazino[2,3-b][1,4]benzothiazine derivatives to be potent ICAM-1 inhibitors. Of these compounds, N-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-N',N'-dimethylsulfamide 7p showed the potent oral inhibitory activities against neutrophil migration in a murine interleukin-1 (IL-1) induced paw inflammation model. The synthesis and structure-activity relationships of these amide derivatives are described.
Collapse
|
10
|
Lin LS, Kopka IE, Mumford RA, Magriotis PA, Lanza T, Durette PL, Kamenecka T, Young DN, de Laszlo SE, McCauley E, Riper GV, Kidambi U, Egger LA, Tong X, Lyons K, Vincent S, Stearns R, Colletti A, Teffera Y, Fenyk-Melody J, Schmidt JA, MacCoss M, Hagmann WK. The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists. Bioorg Med Chem Lett 2002; 12:611-4. [PMID: 11844683 DOI: 10.1016/s0960-894x(01)00818-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Acylated beta-amino acids are described as potent, specific and orally bioavailable antagonists of VLA-4. The initial lead was identified from a combinatorial library. Subsequent optimization using a traditional medicinal chemistry approach led to significant improvement in potency (up to 8-fold) while maintaining good pharmacokinetic properties.
Collapse
Affiliation(s)
- Linus S Lin
- Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|